Anchor Capital Advisors LLC Sells 15,484 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Anchor Capital Advisors LLC trimmed its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 15.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 85,186 shares of the medical research company’s stock after selling 15,484 shares during the period. Anchor Capital Advisors LLC’s holdings in Charles River Laboratories International were worth $15,725,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Creative Planning boosted its position in Charles River Laboratories International by 4.0% in the 3rd quarter. Creative Planning now owns 4,672 shares of the medical research company’s stock valued at $920,000 after buying an additional 180 shares during the last quarter. Forsta AP Fonden boosted its position in shares of Charles River Laboratories International by 11.6% in the 3rd quarter. Forsta AP Fonden now owns 10,600 shares of the medical research company’s stock worth $2,088,000 after purchasing an additional 1,100 shares during the last quarter. State of Alaska Department of Revenue grew its position in shares of Charles River Laboratories International by 2.6% during the 3rd quarter. State of Alaska Department of Revenue now owns 15,899 shares of the medical research company’s stock worth $3,131,000 after buying an additional 405 shares during the period. Iridian Asset Management LLC CT boosted its position in shares of Charles River Laboratories International by 19.2% during the third quarter. Iridian Asset Management LLC CT now owns 55,043 shares of the medical research company’s stock worth $10,842,000 after purchasing an additional 8,876 shares in the last quarter. Finally, Stephens Inc. AR grew its stake in Charles River Laboratories International by 126.9% in the third quarter. Stephens Inc. AR now owns 5,463 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 3,055 shares during the period. 98.91% of the stock is owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now directly owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. This trade represents a 18.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster acquired 6,075 shares of the stock in a transaction on Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the purchase, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This trade represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Down 1.8 %

Charles River Laboratories International stock opened at $164.91 on Friday. The company’s 50-day moving average price is $171.35 and its two-hundred day moving average price is $187.25. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The stock has a market cap of $8.43 billion, a P/E ratio of 1,099.39, a P/E/G ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, beating the consensus estimate of $2.50 by $0.16. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.46 earnings per share. As a group, analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on CRL shares. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Barclays lowered their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 18th. Evercore ISI increased their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. TD Cowen lifted their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, CLSA cut shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target on the stock. in a research report on Monday, November 18th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).